Therefore, finding a strategy to selectively target BCL-XL and MCL-1 in tumors without causing significant on-target toxicity was the primary goal of our current study for treating an important difficult-to-treat subset of SCLC. Here, MCL1 is linked to small cell lung carcinoma.